Psychedelic-assisted therapy is structured as three phases: preparation, dosing, and integration. Public attention — and most patient questions — focus almost entirely on the second of these. The dosing session is novel, vivid, and easy to picture. Yet many clinicians working in this field will say plainly that the integration phase is where the therapy actually happens. Sustained behavioral and symptomatic change — the part that matters in the patient's life weeks and months after the medication has cleared — depends substantially on the quality of the integration work that follows. This article is a Canadian guide to what integration is, why clinicians take it so seriously, how it is typically structured, what approaches are used, and how ATMA CENA's three-phase model handles it.

Key takeaways

Integration is the third phase in the standard preparation + dosing + integration model. It is not optional.

Many clinicians describe integration as where the therapy happens — the dosing session opens material; integration is what turns that material into change.

Typical structure: a first integration session within 24–48 hours of dosing, then weekly sessions for 2–6 weeks (sometimes longer), in individual, group, or peer formats.

What integration accomplishes: sense-making, behavior change, working with difficult material, support-network building, relapse prevention (in SUD contexts), coordinated care coordination with existing providers, and longitudinal symptom tracking.

Approaches include psychodynamic work, Acceptance and Commitment Therapy (ACT), Internal Family Systems (IFS), somatic experiencing and other body-based modalities, and group integration.

Substance-specific differences exist: ketamine integration tends to be shorter and more supplementary; psilocybin protocols (Goodwin 2022 COMP001) included substantial integration weeks; MDMA-AT protocols (Mitchell 2021/2023 MAPP1/MAPP2) included three integration sessions per dosing.

Group integration has emerging evidence in Canada — the Roots to Thrive Nanaimo group model (Dames et al. 2025, Frontiers in Psychiatry) is one published example.

Many patients underestimate integration's importance. Skipping or under-dosing integration is one of the more common reasons single-dose effects plateau or diminish.

What integration is — and what it is not

Integration is the post-dosing phase of psychedelic-assisted therapy in which a clinician (or trained facilitator) and the patient work together to make sense of what happened during the dosing session and translate that material into changes in how the patient lives day to day.

A useful working definition: integration is the clinical and therapeutic process of moving from acute experience to durable change. It is not "decoding the trip." It is not a debrief. It is not a one-off session in which the patient describes the experience and the clinician offers an interpretation. Treating it as any of those things is a common error and one of the reasons single-dose psychedelic effects sometimes plateau.

The framing that integration is where the therapy actually happens comes up consistently in the integration literature (Bossis on existential and meaning-making frameworks; Watts and the ACCEPT model from Imperial College; Earleywine on cannabis and psychedelic harm-reduction integration). The dosing session opens material — emotional, somatic, autobiographical, relational. Without structured integration, that material can fade, fragment, or fail to translate into the changes in behavior and relationship that produce sustained symptomatic improvement.

How the integration phase is typically structured

Integration phase structure varies by substance, indication, and clinical model, but a generally recognizable shape exists across reputable Canadian and international protocols.

The first integration session

The first integration session is typically scheduled for the next day or within 48 hours of dosing. The reason is practical: the dosing experience is freshest, the material most accessible, and the patient most able to articulate what came up while they are still close to the experience. Waiting longer than 48–72 hours risks loss of granular content. This first session tends to be longer — 60 to 90 minutes is typical.

Subsequent sessions

After the first session, integration typically continues weekly for 2 to 6 weeks, occasionally longer for complex cases or in protocols that schedule a second dosing session within a multi-dose course. For courses with several dosing sessions (Spravato induction, IV ketamine series, MDMA-AT), integration sessions are interleaved between dosing sessions.

Formats

Three formats predominate:

Individual psychotherapy integration — one-on-one with a trained therapist; the most common Canadian format and the structure used in ATMA CENA's standard offering.
Group integration — a facilitated group of patients who have completed dosing within a similar window. Group format has its own evidence base (see Roots to Thrive below) and offers collective sense-making patients sometimes find difficult to access in one-on-one work.
Peer support — non-clinical, lay-facilitated support that complements (does not replace) clinical integration. Peer support can extend integration's reach in the months after the formal phase ends.

Many Canadian clinical pathways now combine these — for example, individual integration as the clinical core with optional group integration sessions for community and continuity.

What integration actually accomplishes

A coherent integration phase is doing several distinct kinds of work simultaneously. Naming them is useful because it clarifies why integration is a clinical phase, not a debrief.

1. Sense-making of the dosing experience

Patients often emerge from a dosing session with material that is vivid, emotionally charged, and not yet articulated. The clinician's role is to help the patient put words around it without imposing a "right" interpretation. Reputable integration practice is strongly non-prescriptive on meaning. The patient is the authority on what their experience meant; the clinician supports articulation, contextualization, and connection-making.

2. Translation of insights into behavioral change

This is where integration most directly differs from a debrief. An insight in a dosing session — "I have been avoiding this conflict with my mother for fifteen years" — is, by itself, not therapeutic. The therapeutic work is the change in behavior that follows: the difficult conversation, the boundary, the new pattern. Integration sessions identify candidate behavior changes, troubleshoot obstacles, and follow up on attempts.

3. Working with difficult or challenging material

Dosing sessions can surface trauma, grief, somatic discomfort, or material that was previously unconscious. Integration is where this material is metabolized — slowly, over weeks, in a relationally safe container. This is why integration with a trained clinician matters: bringing up difficult material without skilled support is one of the more common adverse trajectories in psychedelic-assisted work.

4. Building support networks for sustained change

Behavioral change rarely sustains in isolation. Integration sessions help patients identify the relationships, routines, and structural supports that will hold the change in place after formal therapy ends. This is true across indications — TRD, PTSD, substance use, end-of-life distress.

5. Relapse prevention in substance-use disorder contexts

For patients in SUD-context psychedelic-assisted work, integration takes on a specific relapse-prevention character. Sessions identify triggers, build coping plans, and coordinate with existing addictions care. The Roots to Thrive Nanaimo group model (Dames et al. 2025) is one published Canadian example of group integration with explicit attention to this work.

6. Coordination with the existing therapist (coordinated care)

For many Canadian patients, a long-standing therapeutic relationship is already in place. Integration done in isolation from that relationship loses leverage. ATMA CENA's coordinated care model coordinates integration with the patient's existing therapist or psychiatrist — they remain primary, the psychedelic-specific integration layers on top, and material from dosing is brought back into the ongoing relational therapy where the long-term work continues.

7. Tracking symptoms over time post-dosing

Integration sessions are also longitudinal data points. PHQ-9, GAD-7, PCL-5, or condition-specific instruments are typically administered during integration to track response, identify plateau, and inform whether further dosing is clinically appropriate. This is part of how clinicians decide on maintenance strategies for ketamine and Spravato, and how SAP-pathway psilocybin integration tracks durability of response.

Approaches used in integration

There is no single integration modality. Most experienced Canadian clinicians draw from several frameworks depending on the patient and the material.

Psychodynamic integration — emphasis on unconscious material, early-life patterns, and relational dynamics surfaced during dosing. Frequently the right frame for material involving caregivers, attachment, and developmental wounds.
Acceptance and Commitment Therapy (ACT) — emphasis on values clarification, defusion from difficult thoughts, committed action. Strong fit with the "translation to behavior" function of integration. Watts and colleagues at Imperial College have published extensively on ACT-integration overlaps.
Internal Family Systems (IFS) — emphasis on parts work; particularly useful when dosing surfaces material that feels like it came from a younger or wounded "part" of the self. Widely used in MDMA-AT integration in particular.
Somatic experiencing and body-based work — emphasis on what the body holds and how it discharges trauma; strong fit with PTSD and somatic material that arose during dosing.
Group integration — collective sense-making with witnessing and mutual support; the Roots to Thrive evidence base in Canada is the most cited published example.

The point is not that any single approach is correct. The point is that integration is structured therapeutic work using established psychotherapy modalities, applied to material that arose during a psychedelic experience. It is a clinical phase, not a wrap-up.

Substance-specific integration differences

The integration phase looks somewhat different across the principal psychedelic-assisted therapies offered or investigated in Canada.

Ketamine integration

Ketamine integration tends to be shorter in typical course and more psychotherapy-supplementary than psilocybin or MDMA-AT integration. Several factors drive this. Ketamine sessions are shorter (typical IV/IM 40–60 minutes; SL longer). The acute dissociative experience is less narrative, less autobiographical, and often less memory-vivid than a high-dose psilocybin or MDMA experience. The course is longer (Spravato induction is twice weekly for four weeks; off-label IV ketamine often a series of 4–6 sessions), so integration is interleaved with ongoing dosing rather than concentrated after a single experience.

For Spravato specifically, the Health Canada label does not require psychotherapy. Many Canadian clinics nonetheless offer optional integration support, increasingly with evidence that pairing reduces relapse rate. For more detail: Ketamine Therapy in Canada and Group Ketamine Therapy.

Psilocybin integration

Psilocybin integration is typically substantial. The Goodwin 2022 NEJM COMP001 phase 2 protocol (PMID 36322843) explicitly included integration weeks following each dosing session, and the MAGNUS phase 3 program continues this design. Psilocybin dosing produces longer (5–6 hour), more autobiographical and meaning-laden experiences than ketamine; the integration phase therefore carries more material to metabolize. ATMA CENA's SAP-pathway psilocybin work follows this protocol structure.

For more detail: Psilocybin Therapy in Canada and SAP Application Process — Complete Guide.

MDMA-assisted therapy integration

The Mitchell 2021 (MAPP1, Nature Medicine) and Mitchell 2023 (MAPP2, Nature Medicine) MDMA-AT for PTSD protocols included three integration sessions following each of three dosing sessions — nine integration sessions in total over the course. This is the most heavily-integrated of the standard psychedelic-assisted therapy protocols, reflecting both the trauma-focus of the indication and the depth of material MDMA-AT typically surfaces. MDMA remains investigational in Canada under SAP. For deep-dive: MDMA-Assisted Therapy in Canada.

The challenge — patients underestimate integration

A recurring observation across Canadian clinics offering psychedelic-assisted therapy: patients arrive focused on the dosing session and underestimate integration. This is understandable — the dosing session is the unfamiliar, dramatic, easily-pictured part. Integration is a series of psychotherapy sessions, which patients may already feel they understand.

The clinical consequence of underweighting integration shows up in the trajectory of response. Patients who skip or under-attend integration tend to plateau earlier or experience response that diminishes faster than patients who complete the integration phase as designed. This is one of the better-supported clinical observations in the field, even if precise effect sizes are still being established.

A practical solution that works for many Canadian patients is integration through coordinated care with an existing therapist. If you already have a therapist you trust, the long-term integration work can happen with them, layered on top of the psychedelic-specific integration sessions provided by the clinic. This both leverages an existing relationship and extends integration's reach beyond the formal post-dosing window.

Integration-only services and harm-reduction context

A separate question: integration sessions for people who have had a psychedelic experience outside a clinical setting. This is sometimes called integration-only services or post-experience integration. Some Canadian clinicians offer this on a harm-reduction basis. ATMA CENA is not a harm-reduction provider and does not facilitate or endorse non-clinical psychedelic use; we mention it because patients ask. The honest framing is that integration support for self-led experiences is a real and clinically reasonable service that exists in the Canadian landscape, distinct from full psychedelic-assisted therapy programs.

Group integration — the Roots to Thrive model

Group integration has a small but growing Canadian evidence base. The Roots to Thrive program in Nanaimo, BC has published a group-based psilocybin and ketamine model with attention to community, witnessing, and collective sense-making. Dames et al. 2025 in Frontiers in Psychiatry is the most-cited published outcome paper on the model. The findings support group integration as a clinically reasonable adjunct or, in selected populations, primary integration format.

Group integration is not for every patient. Some material is better worked one-on-one. Some patients find group exposure activating in ways that interfere with integration rather than supporting it. The clinical decision to integrate in group, individually, or both is made between patient and clinician. For ATMA CENA's group work in the ketamine context: Group Ketamine Therapy.

What the evidence does — and does not — show

Integration improves durability. The integration literature consistently supports the position that integration is associated with better sustained outcomes than dosing without integration, across substances. Effect sizes are not perfectly characterized.
Integration is essential, not optional. This is the position of the principal published protocols (Mitchell 2021/2023, Goodwin 2022) and of ATMA CENA's clinical model. We do not frame psychedelic-assisted therapy without integration as a complete therapy.
No outcome promises. Integration done well does not guarantee response, and it does not turn a non-responder into a responder. What it does is increase the probability that gains made during the dosing phase translate into changes that persist.
Integration carries risk if done poorly. Material surfaced during dosing can be re-traumatizing if integration is rushed, misframed, or interpretively imposed. This is one reason training and clinical experience matter.

How ATMA CENA handles integration

ATMA CENA's three-phase model treats integration as a clinical phase with the same seriousness as preparation and dosing.

First integration session within 24–48 hours of dosing; longer session.
Weekly sessions for the duration of the integration phase appropriate to the substance and indication.
Coordinated care with the patient's existing therapist or psychiatrist where applicable, so that integration's long-term work happens in the relationship that will continue past the formal psychedelic phase.
Modality flexibility — psychodynamic, ACT, IFS, and somatic frames are all available depending on what the material calls for.
Group integration offered in selected programs where clinically appropriate.
Symptom tracking with validated instruments throughout integration to inform whether further dosing or maintenance is indicated.

Frequently asked questions

Why is integration described as the most important phase? Because sustained therapeutic effect — the part of psychedelic-assisted therapy that matters in the patient's life weeks and months after dosing — depends substantially on integration quality. The dosing session opens material; integration is what turns that material into durable change.

How long is the integration phase? Typically a first session within 24–48 hours of dosing, then weekly sessions for 2–6 weeks. Some patients continue longer-term integration work, often through coordinated care with an existing therapist.

Is integration optional? No. Reputable Canadian psychedelic-assisted therapy programs treat integration as a required clinical phase. Skipping integration is not psychedelic-assisted therapy as the published protocols define it.

What approaches are used in integration? Psychodynamic, Acceptance and Commitment Therapy (ACT), Internal Family Systems (IFS), somatic experiencing and body-based work, and group integration. Most experienced clinicians draw from several frameworks depending on the patient and material.

How is psilocybin integration different from ketamine integration? Psilocybin integration is typically more substantial — longer, more autobiographical material to metabolize, structured around discrete dosing sessions (Goodwin 2022 COMP001 protocol). Ketamine integration is typically shorter and more psychotherapy-supplementary, interleaved with a longer dosing course.

What does MDMA-AT integration look like? The Mitchell 2021/2023 MAPP1 and MAPP2 protocols included three integration sessions following each of three dosing sessions — nine integration sessions in total. MDMA remains investigational in Canada under the Special Access Program.

Can I integrate with my existing therapist? Yes — this is what ATMA CENA's coordinated care model is designed for. Your existing therapist or psychiatrist remains primary, and the psychedelic-specific integration layers on top.

What's group integration and is it as effective as individual? Group integration is facilitated collective sense-making with other patients who have completed dosing in a similar window. Canadian evidence — including the Roots to Thrive Dames et al. 2025 paper — supports group integration as a clinically reasonable format. Whether group, individual, or both is right is a clinical decision made between patient and clinician.

What if I had a difficult experience during dosing? This is exactly what integration is for. Difficult or challenging material — including trauma, grief, or somatic discomfort that surfaced during dosing — is metabolized in integration over weeks, in a relationally safe container with a trained clinician.

Do I need integration if I'm doing Spravato? The Spravato Health Canada label does not require psychotherapy. Many Canadian Spravato clinics nonetheless offer optional integration support, and increasing clinical experience suggests pairing reduces relapse rate. See Ketamine Therapy in Canada.

Is integration covered by insurance? Coverage for integration psychotherapy follows standard Canadian psychotherapy reimbursement — typically through extended health benefits where the clinician's license category (psychologist, social worker, RP) is covered. Substance-specific coverage (Spravato, off-label ketamine, SAP psilocybin) is separate.

Sources

Mitchell JM, Bogenschutz M, Lilienstein A, et al. (2021). MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study (MAPP1). Nature Medicine, 27(6):1025-1033. PMID: 33972795.
Mitchell JM, Ot'alora G M, van der Kolk B, et al. (2023). MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial (MAPP2). Nature Medicine, 29(10):2473-2480. PMID: 37709999.
Goodwin GM, Aaronson ST, Alvarez O, et al. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression (COMP001). New England Journal of Medicine, 387(18):1637-1648. PMID: 36322843.
Dames S, Kryskow P, Watler C, et al. (2025). Group-based psychedelic-assisted therapy in community mental health: outcomes from the Roots to Thrive program. Frontiers in Psychiatry (Roots to Thrive Nanaimo group integration model).
Watts R, Day C, Krzanowski J, Nutt D, Carhart-Harris R. (2017). Patients' Accounts of Increased "Connectedness" and "Acceptance" After Psilocybin for Treatment-Resistant Depression. Journal of Humanistic Psychology, 57(5):520-564.
Watts R, Luoma JB. (2020). The use of the psychological flexibility model to support psychedelic-assisted therapy. Journal of Contextual Behavioral Science, 15:92-102.
Bossis AP, Ross S, Guss J. (2014). Psilocybin-Generated Experience in the Treatment of Existential Distress and Psychiatric Symptoms in Patients with Life-Threatening Cancer. NYU Langone clinical program literature.
Earleywine M, Mian MN, Altman BR, De Leo JA. (2022). Integration in psychedelic-assisted treatments: recurring themes in current providers' definitions, challenges, and methods. Journal of Humanistic Psychology (open-access).
Carhart-Harris R, Giribaldi B, Watts R, et al. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15):1402-1411. PMID: 33852780.
Health Canada — Special Access Program: https://www.canada.ca/en/health-canada/services/drugs-health-products/special-access.html
Health Canada — SAP psychedelic-assisted psychotherapy announcement: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html
Health Canada — Spravato Notice of Compliance and Product Monograph: https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98903
Compass Pathways — MAGNUS phase 3 program (COMP005, COMP006): https://compasspathways.com/our-research/comp360-clinical-program/
Roots to Thrive — group-based psychedelic-assisted therapy program description: https://rootstothrive.com/

Last updated: 2026-05-06

The Integration Phase of Psychedelic-Assisted Therapy — Why It's the Most Important Phase